1. Home
  2. FIHL vs AUPH Comparison

FIHL vs AUPH Comparison

Compare FIHL & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fidelis Insurance Holdings Limited

FIHL

Fidelis Insurance Holdings Limited

HOLD

Current Price

$21.32

Market Cap

2.0B

Sector

N/A

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$16.15

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIHL
AUPH
Founded
2014
1993
Country
Bermuda
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
FIHL
AUPH
Price
$21.32
$16.15
Analyst Decision
Hold
Buy
Analyst Count
7
4
Target Price
$22.79
$17.25
AVG Volume (30 Days)
408.2K
1.0M
Earning Date
05-13-2026
05-11-2026
Dividend Yield
2.82%
N/A
EPS Growth
N/A
5075.00
EPS
N/A
2.07
Revenue
N/A
$283,055,000.00
Revenue This Year
$15.94
$17.54
Revenue Next Year
$7.04
$15.74
P/E Ratio
N/A
$7.78
Revenue Growth
N/A
20.38
52 Week Low
$14.80
$7.29
52 Week High
$21.40
$16.88

Technical Indicators

Market Signals
Indicator
FIHL
AUPH
Relative Strength Index (RSI) 71.60 60.05
Support Level $17.93 $14.56
Resistance Level N/A $16.32
Average True Range (ATR) 0.45 0.44
MACD 0.13 0.02
Stochastic Oscillator 97.75 44.15

Price Performance

Historical Comparison
FIHL
AUPH

About FIHL Fidelis Insurance Holdings Limited

Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: